1. Home
  2. CRSP vs IEP Comparison

CRSP vs IEP Comparison

Compare CRSP & IEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

N/A

Current Price

$50.34

Market Cap

4.8B

Sector

Health Care

ML Signal

N/A

Logo Icahn Enterprises L.P.

IEP

Icahn Enterprises L.P.

N/A

Current Price

$4.85

Market Cap

4.7B

ML Signal

N/A

Company Overview

Basic Information
Metric
CRSP
IEP
Founded
2013
1987
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.7B
IPO Year
2016
1994

Fundamental Metrics

Financial Performance
Metric
CRSP
IEP
Price
$50.34
$4.85
Analyst Decision
Buy
Analyst Count
23
0
Target Price
★ $85.42
N/A
AVG Volume (30 Days)
1.3M
★ 1.8M
Earning Date
11-02-2026
11-03-2026
Dividend Yield
N/A
★ 42.10%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
$289,590,000.00
★ $9,658,000,000.00
Revenue This Year
$910.97
$1.70
Revenue Next Year
$277.83
$6.64
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 9169.85
N/A
52 Week Low
$44.12
$4.73
52 Week High
$63.45
$9.10

Technical Indicators

Market Signals
Indicator
CRSP
IEP
Relative Strength Index (RSI) 47.79 19.96
Support Level $50.02 N/A
Resistance Level $60.68 $7.80
Average True Range (ATR) 2.44 0.27
MACD 0.06 -0.07
Stochastic Oscillator 36.10 5.95

Price Performance

Historical Comparison
CRSP
IEP

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About IEP Icahn Enterprises L.P.

Icahn Enterprises LP provides diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.

Share on Social Networks: